Nuvalent (NUVL)
(Real Time Quote from BATS)
$77.61 USD
-1.51 (-1.91%)
Updated Jul 30, 2024 03:42 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NUVL 77.61 -1.51(-1.91%)
Will NUVL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Why Earnings Season Could Be Great for Nuvalent (NUVL)
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
Other News for NUVL
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
Nuvalent initiated with a Not Rated at Goldman Sachs
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
Nuvalent: Making Precise Progress In Its Oncology Pipeline